Full Press Release Details
Life Sciences Ltd Reports Annual Results for the Twelve Months Ended
December 31, 2022, and Corporate Update
YORK, April 26, 2023 - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology
company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the
twelve months ended December 31, 2022, and provided a corporate update on its lead programs in development.
Cerrone, Executive Chairman, founder and interim Chief Executive Officer of Tiziana, commented, "After announcing our focus on
advancing intranasal foralumab to address CNS-mediated inflammatory diseases, we have started this year with a stream of continuous,
positive program-related developments. Intranasal foralumab's unique action on regulatory
T-cells and its potential to treat multiple inflammatory pathology indications has been published in a major medical journal and recognized
in the media. We also recently announced intranasal foralumab's potential to treat Long Covid, Alzheimer's and Type 1 diabetes.
Our near-term strategic focus is to prioritize resources for the clinical development of this unique therapeutic candidate to
maximize shareholder value while still maintaining optionality for our other research programs, including milciclib in oncology. We aim
to become a leading company pioneering intranasal therapies for inflammatory diseases".
Quarter 2022 Developments Related to Foralumab
Recent Clinical Program Updates
Year End Financial Results
Annual Report on Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Investors section of the
Company's website at ir.tizianalifesciences.com/financial-information/annual-reports.
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation
by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1
Tiziana Life Sciences
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab,
which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies
to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is
expected to allow for broad pipeline applications.
Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC